Scarica l'app Stockscreener
10.17
0.20%
0.02
Iteos Therapeutics Inc Borsa (ITOS) Ultime notizie
Wedbush Research Analysts Cut Earnings Estimates for ITOS - Defense World
iTeos Therapeutics Inc. Stock Analysis and ForecastRecord-breaking capital gains - PrintWeekIndia
Will iTeos Therapeutics Inc. stock split in the near futureHigh-yield investments - jammulinksnews.com
Q2 EPS Estimate for iTeos Therapeutics Lowered by Analyst - Defense World
SHAREHOLDER ALERT: Morris Kandinov Investigating AVDX, - GlobeNewswire
What analysts say about iTeos Therapeutics Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
Is iTeos Therapeutics Inc. stock overhyped or has real potentialFree Predictions - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceRapid growth opportunities - Autocar Professional
Assessing the Fairness of iTeos Therapeutics' $10.047-per-Share Acquisition Offer: A Valuation Deep Dive - AInvest
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc.ITOS - The Globe and Mail
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter
Concentra buys beleaguered iTeos at slight discount - PharmaLive
iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com Canada
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of ITeos Therapeutics, Inc. - 富途牛牛
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc. - ETX View
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - The Globe and Mail
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):